TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Xbrane Biopharma AB
Closing information (x1000 EUR)
Closing information | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Turnover | 5,178 | 0 | 0 |
Financial expenses | 206 | 258 | 77 |
Earnings before taxes | -15,143 | -17,916 | -22,518 |
EBITDA | -14,268 | -16,463 | |
Total assets | 62,050 | 67,315 | 46,203 |
Current assets | 46,146 | 54,856 | 37,308 |
Current liabilities | 21,258 | 21,479 | 18,829 |
Equity capital | 38,181 | 42,216 | 25,675 |
- share capital | 554 | 549 | 344 |
Employees (average) | 68 | 50 | 39 |
Financial ratios
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Solvency | 61.5% | 62.7% | 55.6% |
Turnover per employee | 76 | 0 | 0 |
Profit as a percentage of turnover | -292.4% | ||
Return on assets (ROA) | -24.1% | -26.2% | -48.6% |
Current ratio | 217.1% | 255.4% | 198.1% |
Return on equity (ROE) | -39.7% | -42.4% | -87.7% |
Change turnover | 5,178 | 0 | 0 |
Change turnover % | |||
Chg. No. of employees | 18 | 11 | 3 |
Chg. No. of employees % | 36% | 28% | 8% |
Total value of public sale
Fiscal year | 2022/12 (consolidated) | 2021/12 (consolidated) | 2020/12 (consolidated) |
Total value of public sale | 0 | 0 | 0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.